142 related articles for article (PubMed ID: 24959994)
1. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
2. Preventing broken hearts in women with breast cancer: a concise review on chemotherapy-mediated cardiotoxicity.
Bews HJ; Mackic L; Jassal DS
Can J Physiol Pharmacol; 2023 Dec; ():. PubMed ID: 38039515
[TBL] [Abstract][Full Text] [Related]
3. The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.
Walker JR; Singal PK; Jassal DS
Exp Clin Cardiol; 2009; 14(3):e62-7. PubMed ID: 20098570
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of Agents Used in Patients With Breast Cancer.
Zagami P; Trapani D; Nicolò E; Corti C; Valenza C; Criscitiello C; Curigliano G; Carey LA
JCO Oncol Pract; 2024 Jan; 20(1):38-46. PubMed ID: 37983586
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.
Xie Y; Collins WJ; Audeh MW; Shiao SL; Gottlieb RA; Goodman MT; Merz CN; Mehta PK
Curr Treat Options Cardiovasc Med; 2015 Dec; 17(12):60. PubMed ID: 26490280
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.
Zeglinski M; Ludke A; Jassal DS; Singal PK
Exp Clin Cardiol; 2011; 16(3):70-4. PubMed ID: 22065936
[TBL] [Abstract][Full Text] [Related]
7. [Cardiac Dysfunction and Arterial Hypertension as Manifestations of Cardiovasculotoxicity of iVEGF-Containing Chemotherapy. Clinical Case].
Kirichenko YY; Kulagina TY; Zhigulina OA; Ilgisonis IS; Belenkov YN
Kardiologiia; 2024 May; 64(5):33-38. PubMed ID: 38841787
[TBL] [Abstract][Full Text] [Related]
8. Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy.
Gabani M; Castañeda D; Nguyen QM; Choi SK; Chen C; Mapara A; Kassan A; Gonzalez AA; Khataei T; Ait-Aissa K; Kassan M
Cureus; 2021 Sep; 13(9):e18194. PubMed ID: 34589374
[TBL] [Abstract][Full Text] [Related]
9. Pulse check: Exploring the potential of the shock index as a biomarker for cancer-therapy-related cardiotoxicity in breast cancer patients.
Nohria A; Ben Zadok OI
J Nucl Cardiol; 2024 May; 35():101861. PubMed ID: 38604494
[No Abstract] [Full Text] [Related]
10. A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging.
Linders AN; Dias IB; López Fernández T; Tocchetti CG; Bomer N; Van der Meer P
NPJ Aging; 2024 Jan; 10(1):9. PubMed ID: 38263284
[TBL] [Abstract][Full Text] [Related]
11. Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics.
Li Y; Ju L; Hou Z; Deng H; Zhang Z; Wang L; Yang Z; Yin J; Zhang Y
J Proteome Res; 2015 Jun; 14(6):2437-45. PubMed ID: 25919346
[TBL] [Abstract][Full Text] [Related]
12. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.
Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C
Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.
Onitilo AA; Engel JM; Stankowski RV
Ther Adv Drug Saf; 2014 Aug; 5(4):154-66. PubMed ID: 25083270
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.
Marinko T; Dolenc J; Bilban-Jakopin C
Radiol Oncol; 2014 Jun; 48(2):105-12. PubMed ID: 24991199
[TBL] [Abstract][Full Text] [Related]
15. Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity.
Beaumier A; Robinson SR; Robinson N; Lopez KE; Meola DM; Barber LG; Bulmer BJ; Calvalido J; Rush JE; Yeri A; Das S; Yang VK
J Vet Intern Med; 2020 May; 34(3):1260-1271. PubMed ID: 32255536
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Huang G; Zhai J; Huang X; Zheng D
Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
[TBL] [Abstract][Full Text] [Related]
17. Aspalathin Reverts Doxorubicin-Induced Cardiotoxicity through Increased Autophagy and Decreased Expression of p53/mTOR/p62 Signaling.
Johnson R; Shabalala S; Louw J; Kappo AP; Muller CJF
Molecules; 2017 Sep; 22(10):. PubMed ID: 28937626
[TBL] [Abstract][Full Text] [Related]
18. Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.
Gilliam LA; Lark DS; Reese LR; Torres MJ; Ryan TE; Lin CT; Cathey BL; Neufer PD
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E293-301. PubMed ID: 27329802
[TBL] [Abstract][Full Text] [Related]
19. Stem cells: The cancer's gone, but did chemotherapy damage your heart?
Bellin M; Mummery CL
Nat Rev Cardiol; 2016 Jul; 13(7):383-4. PubMed ID: 27226155
[No Abstract] [Full Text] [Related]
20. Detection of Cardiac Toxicity Due to Cancer Treatment: Role of Cardiac MRI.
Meyersohn NM; Pursnani A; Neilan TG
Curr Treat Options Cardiovasc Med; 2015 Aug; 17(8):396. PubMed ID: 26134969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
